HOXD13 and cancer: Similar results were observed for patient survival by sPD-1/PD-L1 ratio in melanoma treated with immune checkpoint blockade (69), as well as in the context of low sPD-1 and high sPD-L1 combination for PD-1 antibody monotherapy across various cancers (70).